Literature DB >> 3680513

Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.

E M Conway1, K A Bauer, S Barzegar, R D Rosenberg.   

Abstract

RIAs for hemostatic system activation were employed to study patients who were anticoagulated with warfarin. The mean prothrombin fragment F1 + 2 concentration in stably anticoagulated individuals without an inherited thrombotic diathesis (mean prothrombin time [PT] ratio [PT of patient/PT of normal plasma pool] = 1.74) was 0.231 nM as compared with a mean plasma F1 + 2 level of 1.68 nM for a nonanticoagulated control group (P less than 0.0001). The initiation of oral anticoagulants in two subjects who did not exhibit protein C deficiency led to a paradoxical increase in F1 + 2 levels during the first day of therapy. We have also shown that a relatively low intensity regimen of warfarin (PT ratio less than 1.2) may reduce elevated concentrations of F1 + 2 into the normal range in patients with a history of recurrent thromboembolism. The mean F1 + 2 level in antithrombin-deficient individuals on warfarin was significantly elevated (mean = 0.714 nM) as compared with that in anticoagulated subjects with protein C deficiency (mean = 0.205 nM) or in those without an inherited thrombotic disorder (P less than 0.01) at equivalent levels of intensity of oral anticoagulation. We therefore conclude that the effect of warfarin on hemostatic system activation is modulated by the endogenous heparan sulfate-antithrombin mechanism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680513      PMCID: PMC442421          DOI: 10.1172/JCI113239

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Quantitative determination of gamma-carboxyglutamic acid in proteins.

Authors:  P V Hauschka
Journal:  Anal Biochem       Date:  1977-05-15       Impact factor: 3.365

2.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.

Authors:  K A Bauer; L M Weiss; D Sparrow; P S Vokonas; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

3.  Anticoagulant properties of bovine plasma protein C following activation by thrombin.

Authors:  W Kisiel; W M Canfield; L H Ericsson; E W Davie
Journal:  Biochemistry       Date:  1977-12-27       Impact factor: 3.162

4.  Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.

Authors:  C T Esmon; W G Owen
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

5.  Vitamin K and the biosynthesis of prothrombin. V. Gamma-carboxyglutamic acids, the vitamin K-dependent structures in prothrombin.

Authors:  P Fernlund; J Stenflo; P Roepstorff; J Thomsen
Journal:  J Biol Chem       Date:  1975-08-10       Impact factor: 5.157

6.  Determination of plasma protein S--the protein cofactor of activated protein C.

Authors:  R M Bertina; A van Wijngaarden; J Reinalda-Poot; S R Poort; V J Bom
Journal:  Thromb Haemost       Date:  1985-04-22       Impact factor: 5.249

7.  The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.

Authors:  H L Nossel; M Ti; K L Kaplan; K Spanondis; T Soland; V P Butler
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

8.  Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex.

Authors:  J M Teitel; K A Bauer; H K Lau; R D Rosenberg
Journal:  Blood       Date:  1982-05       Impact factor: 22.113

9.  Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

Authors:  R Hull; J Hirsh; R Jay; C Carter; C England; M Gent; A G Turpie; D McLoughlin; P Dodd; M Thomas; G Raskob; P Ockelford
Journal:  N Engl J Med       Date:  1982-12-30       Impact factor: 91.245

10.  Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan.

Authors:  J A Marcum; D H Atha; L M Fritze; P Nawroth; D Stern; R D Rosenberg
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

View more
  17 in total

1.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations.

Authors:  Olav Reikerås; Torkil Clementsen
Journal:  J Thromb Thrombolysis       Date:  2008-12-06       Impact factor: 2.300

3.  Characteristics of fibrin formation and clot stability in individuals with congenital type IIb protein C deficiency.

Authors:  J H Foley; L Ferris; K E Brummel-Ziedins
Journal:  Thromb Res       Date:  2012-01-13       Impact factor: 3.944

4.  Warfarin-related recurrent knee haemarthrosis treated with arterial embolisation and intra-articular injection of tranexamic acid.

Authors:  Yasuo Kunugiza; Yoshiharu Nakamura; Koji Mikami; Shozo Suzuki
Journal:  BMJ Case Rep       Date:  2015-07-03

5.  Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1 + 2 and thrombin-antithrombin III complex.

Authors:  G Hafner; H Schinzel; W Ehrenthal; C Wagner; U Konheiser; R Zotz; J Lotz; R Blank; L S Weilemann; W Prellwitz
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

6.  Anticoagulation after intracoronary stent insertion.

Authors:  M J Brack; P J Hubner; A H Gershlick
Journal:  Br Heart J       Date:  1994-09

Review 7.  Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.

Authors:  G Palareti; C Legnani
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

8.  Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: usefulness of coagulation markers for evaluation of efficacy.

Authors:  Takao Urabe; Ryota Tanaka; Kazuyuki Noda; Yoshikuni Mizuno
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

9.  Monitoring prothrombin fragment 1 + 2 during initiation of oral anticoagulant therapy after intracoronary stenting.

Authors:  G Hafner; H Swars; R Erbel; W Ehrenthal; H J Rupprecht; J Lotz; J Meyer; W Prellwitz
Journal:  Ann Hematol       Date:  1992-08       Impact factor: 3.673

Review 10.  Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention.

Authors:  Ferruccio De Lorenzo; Neelam Saba; Vijay V Kakkar
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.